問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Hematology & Oncology

China Medical University Hospital-Taipei (在職)

Division of Thoracic Medicine

更新時間：2023-09-19

夏德椿Hsia, Te-Chun
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 10 個月

  • d1914@mail.cmuh.org.tw

Recruiting Trial

51Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

夏德椿

List

166Cases

2011-08-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2016-01-01 - 2018-12-26

Phase III

SB8

  • Condition/Disease

    NSCLC

  • Test Drug

    SB8

Participate Sites
7Sites

Terminated5Sites

夏德椿
China Medical University Hospital-Taipei

未分科

劉劍英
Linkou Chang Gung Medical Foundation

Division of General Internal Medicine

2015-06-02 - 2019-11-30

Phase II

A Phase 2, multicenter, randomized, double-blind study of ficlatuzumab plus erlotinib versus placebo plus erlotinib in subjects who have previously untreated metastatic, EGFR-mutated non-small cell lung cancer (NSCLC) and BDX004 Positive Label.

  • Condition/Disease

    NSCLC

  • Test Drug

    Ficlatuzumab (AV-299),

Participate Sites
8Sites

Terminated7Sites

夏德椿
China Medical University Hospital-Taipei

未分科

陳育民
Taipei Veterans General Hospital

Division of Thoracic Medicine

2015-01-01 - 2018-12-31

Phase III

Multicentre, randomised, double-blind, Phase III trial to investigate the efficacy and safety of oral nintedanib plus docetaxel therapy compared to placebo plus docetaxel therapy in patients with stage IIIB/IV or recurrent, adenocarcinoma subtype non-small cell lung cancer after failure of first line chemotherapy

  • Condition/Disease

    stage IIIB/IV or recurrent, adenocarcinoma subtype non-small cell lung cancer

  • Test Drug

    Nintedanib

Participate Sites
6Sites

Terminated6Sites

2016-03-20 - 2019-01-20

Phase II

A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed alone in Patients with Heregulin Positive, Locally Advanced or Metastatic, Non-Small Cell Lung Cancer

  • Condition/Disease

    NSCLC

  • Test Drug

    MM-121

Participate Sites
4Sites

Terminated3Sites

夏德椿
China Medical University Hospital-Taipei

未分科

2009-11-01 - 2011-08-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Study ended3Sites

2006-10-01 - 2009-10-30

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2008-10-31 - 2012-10-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2011-04-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2013-07-01 - 2021-06-30

Phase II

A Randomized, Controlled Phase 2 Study Evaluating LY2875358 plus Erlotinib versus Erlotinib as First-Line Treatment in Metastatic Non–Small Cell Lung Cancer Patients with Activating EGFR Mutations Who Have Disease Control after an 8-Week Lead-In Treatment with Erlotinib

  • Condition/Disease

    Non–Small Cell Lung Cancer

  • Test Drug

    LY2875358

Participate Sites
5Sites

Terminated5Sites

夏德椿
China Medical University Hospital

Division of Thoracic Medicine

1 12 13 14 15 16 17
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB